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Abstract 
Background: Malaria is a major parasitic disease, affecting millions of people in endemic areas. Plasmodium falcipa-
rum parasites are responsible for the most severe cases and its resistance to anti‑malarial drugs is notorious. This is 
a possible obstacle to the effectiveness of intermittent preventive treatment (IPT) based on sulfadoxine–pyrimeth‑
amine (SP) cures administrated to pregnant women (IPTp) during their pregnancy. As this intervention is recom‑
mended in Angola since 2006, it has assessed, in this country, the molecular profiles in P. falciparum dhfr and dhps, two 
polymorphic genes associated to pyrimethamine and sulfadoxine resistance, respectively.
Methods: Blood samples from 52 falciparum patients were collected in Lubango, Angola and pfdhfr and pfdhps 
polymorphisms were analysed using nested‑PCR and DNA sequencing.
Results: In the pfdhfr gene, the 108N mutation was almost fixed (98 %), followed by 59R (63 %), 51I (46 %), 50R and 
164L (2 %, respectively). No 16V/S mutations were found. The most common double mutant genotype was CNRN 
(59 + 108; 46 %), followed by CICN (51 + 108; 29 %) whereas IRN (51 + 59 + 108; 15 %), CNRNVL (59 + 108 + 164; 
2 %) and RICN (50 + 51 + 108; 2 %) triple mutant genotypes were detected. Investigations of the pfdhps gene 
showed that the 437G mutation was the most prevalent (97 %). Only two and one samples disclosed the 540E 
(7 %) and the 436A (3 %), respectively. Single mutant SGKAA (437; 86 %) was higher than SGEAA (437 + 540; 7 %) or 
AGKAA (436 + 437; 3 %) double mutants genotypes. No polymorphism was detected at codons 581G and 613T/S. 
Combining pfdhfr and pfdhps alleles two triple mutant haplotypes (double mutant in dhfr and single mutant in dhps) 
were observed: the ACICNVI/SGKAA in 14 (56 %) samples and the ACNRNVI/SGKAA in five (20 %) samples. One 
quadruple mutant haplotype was detected (ACIRNVI/SGKAA) in six (24 %) P. falciparum samples. No quintuple pfdhfr–
pfdhps mutant was noted.
Conclusion: pfdhfr and pfdhps gene mutations in isolates from Lubango are suggestive of a low‑grade SP resistance 
and IPT for pregnant women and infant based on SP treatment could be effective. Routine molecular studies target‑
ing polymorphism in these two genes need to be routinely conducted at country level.
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Background
Plasmodium falciparum malaria is the one of the major 
cause of morbidity and mortality in sub-Saharan Africa, 
including Angola, where three million clinical cases and 
6000 deaths occurred in 2015. The deaths reported in 
Angola territory, accounting for 35  % in children under 
five years old and 25 % of the maternal deaths (Angolan 
National Malaria Control Programme, 2015).
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In endemic malaria communities pregnant women and 
infants are more vulnerable to malaria episodes [1]. The 
World Health Organization strategy to protect mothers 
during their pregnancy and consequences in newborns 
such as low weight includes the implementation of inter-
mittent preventive treatment in pregnant women (IPTp) 
[2]. This treatment was introduced in Angola in 2006, 
using the sulfadoxine–pyrimethamine (SP) at the second 
trimester of pregnancy. However, the emergence of P. fal-
ciparum resistances to both sulfadoxine and pyrimeth-
amine can jeopardize these strategies.
Sulfadoxine–pyrimethamine resistant parasites are 
frequent in Southeast Asia and are becoming more and 
more prevalent in several East African countries [3]. SP 
acts by inhibiting the P. falciparum dihydrofolate reduc-
tase (dhfr) and dihydropteroate synthetase (dhps), two 
fundamental enzymes involved in the folate biosynthesis 
pathway [4]. Single nucleotide polymorphisms (SNPs) 
leading non-synonymous mutations in these two genes 
have been shown to be associated with pyrimethamine 
(dhfr) and sulfadoxine (dhps) resistances. The Angolan 
National Malaria Control Programme intends to intro-
duce IPT in infants, as has already been done in other 
sub-Saharan Africa countries. To inform current policy 
makers when recommending the use of SP in IPT, dhfr 
and dhps molecular markers are used to differentiate 
high and low grade SP resistance areas and to define its 
geographical distribution [5].
Malaria is endemic throughout Angola, but the trans-
mission patterns is heterogenous varying from intense 
transmission and hyperendemicity in northern, meso-
endemic stable in the centre, to seasonal or epidemic 
unstable malaria in the southern part of the country 
[6]. No study for investigating pfdhfr and pfdhps muta-
tions was performed in southern part of Angola where 
Lubango is located. The great majority of previous stud-
ies were conducted at the northern in Luanda, [7, 8]; 
Uige [9, 10], Cabinda, Kwanza Norte and Malanje [10], 
followed by those at the Central Angola in Benguela [11] 
and Huambo [10].
The objective of this study was to investigate the poly-
morphism at codons A16V/S, C50R, N51I, C59R, S108N, 
V140L and I164L in the pfdhfr gene and at codons 
S436A/F/C, A437G, K540E, A581G and A613T/S in the 
pfdhps gene, in order to provide baseline data regarding 
the proportion of P. falciparum pfdhfr and pfdhps muta-
tions, before SP-IPTi introduction in Lubango, an Ango-
lan malaria stable transmission region.
Methods
Study site, blood samples and DNA extraction
Blood samples were collected  in 2011 from 52 patients 
presenting falciparum malaria at the Central Hospital in 
Lubango, located in Huila Province, South of Luanda, 
Angola capital. Lubango is located in southern Angola, 
with an area of 79,022 Km2, 1790 m above sea level, with 
an estimated population of 1,414,115. Malaria transmis-
sion occurs throughout the year, with peaks during rainy 
season, between March and May. Malaria is mesoen-
demic and P. falciparum is the predominant malaria 
species. Inclusion criteria comprised individuals with P. 
falciparum aging over 12 years and no evidence of com-
plicated malaria. The Central Hospital is the main health 
facility in Lubango and it is a reference for malaria in 
the area. The malaria diagnosis was performed by thick 
blood smear and nested-PCR, as previous described 
[12]. All malaria cases were treated following the Ango-
lan malaria treatment policy. After obtaining informed 
consent, venous blood collection was performed accord-
ing to protocols approved by the National Institute of 
Public Health and the Ethical Committee of Angola 
and Fiocruz, Brazil (#372/07). The samples were cryo-
preserved and stored at −20  °C until DNA extraction. 
Genomic DNA was extracted from 1  mL whole blood 
using the QIAamp Midi columns (Qiagen), as described 
by the manufacturer.
Nested polymerase chain reaction (PCR) 
and electrophoresis
pfdhfr and pfdhps genes were amplified by nested-PCR 
approach using two gene-specific primers (external and 
internal) as already reported [13]. The nested-PCRs were 
performed to detect the presence of mutations at codons: 
A16V/S, C50R, N51I, C59R, S108N, V140L and I164L 
in the pfdhfr gene and at codons S436A/F/C, A437G, 
K540E, A581G and A613T/S in the pfdhps gene. The 
choice of these codons was based on the pioneer study of 
Pearson and colleagues [13].
DNA sequencing and SNP polymorphisms detection
After purification of the amplicons using the Wizard SV 
Gel and PCR Clean-Up System (Promega), PCR prod-
ucts were sequenced using Big Dye® Terminator Cycle 
Sequencing Ready Reaction version 3.1 (Applied Biosys-
tems) and ABI PRISM 3730 DNA Analyzer [14] at the 
Genomic Platform/PDTIS/Fiocruz. The sequences of the 
amplicons were aligned with the wild-type 3D7 strain 
for pfdhfr (GenBank accession number XM_001351443) 
and for pfdhfr (GenBank accession number Z30654). 
The presence of SNPs was confirmed by reading both 
the forward and the reverse strands using the free soft-
ware Bioedit Sequence Alignment Editor Version 7.2.5. 
Parasites with mixed alleles (in which both wild-type and 
mutant alleles were present) were considered mutants for 
estimation of the prevalence of the SNPs. Haplotypes for 
drug resistance markers were reconstructed from the full 
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sequence presenting an unambiguous single allele sig-
nal at all positions. Statistical significance of differences 
between the haplotypes was assessed using Fisher’s tests 
and a p value <0.05 was considered significant.
Results
Among the 52 successfully sequenced samples for dhfr, 
51 (98 %) showed non-synonymous mutations. The most 
frequent mutation was 108N (51/52; 98 %, 95 % CI) fol-
lowed by 59R (33/52; 63 %, 95 % CI) and 51I (24/52; 46 %, 
95 % CI). The 50R and 164L mutations were detected at 
the same frequencies (1/52; 2 %, 95 % CI) and no muta-
tions were found at codons 16V/S and 140L (Table 1).
Double mutants (51I/108N, 59R/108N) were observed 
in 39 isolates (76.5  %; 39/51) and triple mutants 
(51I/59R/108N, 50R/51I/108N, 59R/108N/164L) in 
ten (19.5  %; 10/51) P. falciparum samples. The 108N 
single mutant was found in only two (4  %; 2/51) iso-
lates (Table 1). In samples presenting dhfr double muta-
tion, the CNRN (59 + 108) allele was the most frequent 
(24/46  %) followed by CICN (51  +  108) (15/29  %). 
This contrasts with the frequency of the dhfr triple 
mutant alleles which were detected at lower rates: IRN 
(51 + 59 + 108), CNRNVL (59 + 108 + 164) and RICN 
(50 +  51 +  108) (8 (15 %), 1 (2 %) and 1 (2 %), respec-
tively). The wild-type ACNCSVI was presented in only 
one isolate (Tables 2 and 3). 
Of the 52 samples tested, 29 (56  %) were successfully 
amplified for the dhps gene. Among them 28 (97 %) pre-
sented a mutation at codons S436A, A437G and K540E. 
The 437G mutant allele was highly prevalent (97  %), 
while the 540E (7  %) and 436A (3  %) were observed in 
lower frequencies. No 581G and 613T/S alleles were 
observed (Table  1). The frequency of the single mutant 
SGKAA (437) (25/86 %) was higher than double mutants 
SGEAA (437  +  540) (2/7  %) or AGKAA (436  +  437) 
(1/3 %) (p < 0.05). The dhps wild-type SAKAA was rare 
and observed in only one (3  %) P. falciparum sample 
(Tables 2 and 3).
Combining pfdhfr and pfdhps alleles, not all isolates 
had an interpretable haplotype (Table 4). The PCR ampli-
fication failure rate of the dhps gene in Lubango samples 
might be somehow attributed to primer mismatched 
due to unknown polymorphisms in target sequences, 
because in all the 52 samples amplification was achieved 
when primers strictly developed to amplify conserved 
sequences for diagnosis purposes were tested [12]. The 
number of samples herein considered was based on 
amplification of both PCRs just to avoid the identification 
of incomplete haplotypes.
Two triple mutant haplotypes (double mutant in dhfr 
and single mutant in dhps) were observed: the ACIC-
NVI/SGKAA in 14 (56  %) samples and the ACNRNVI/
SGKAA in five (20  %) samples. One quadruple mutant 
haplotype was detected (ACIRNVI/SGKAA) in six (24 %) 
P. falciparum samples (Table 4). The high-grade SP resist-
ant haplotypes (quintuple, sextuple and septuple pfdhfr/
pfdhps) [3] were not seen among these isolates.
Table 1 Plasmodium falciparum dhfr and  dhps mutated 
codons in parasites from Lubango, Angola
Gene SNPs Prevalence
N (%)












Table 2 Prevalence of P. falciparum dhfr and dhps mutants 
in parasites from Lubango, Angola
Gene Mutation SNPs Prevalence
N (%)
dhfr n = 51 Single S108N 2 (4)
Double N51I/S108N 15 (29)
C59R/S108N 24 (47)
Triple N51I/C59R/S108N 8 (16)
C50R/N51I/S108N 1 (2)
C59R/S108N/I164L 1 (2)
dhps n = 28 Single A437G 25 (89)
Double A437G/K540E 2 (7)
S436A/A437G 1 (4)
Table 3 Deduced haplotype profiles for  dhfr  and  dhps P. 
falciparum parasites from Lubango, Angola
Gene Haplotypes N %
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Discussion
At present, SP continues to be used in IPTp and IPTi 
strategies, which are likely to provide sub-optimal effect. 
Therefore, monitoring the spread of SP resistance using 
dhfr and dhps as molecular markers are strongly rec-
ommended [15]. This study was performed with P. fal-
ciparum samples from Lubango, an Angola region with 
unstable meso-endemic malaria transmission. The vast 
majority of tested isolates (98  %) presented at least one 
mutation in the gene encoding enzymes associated with 
pyrimethamine resistance.
High prevalence of 108N mutation (considered as the 
initial mutation occurring in dhfr multiple mutants) was 
detected, similar to observations already done in several 
Angolan regions [8, 10, 11] and in other African coun-
tries [16–26]. However, contrary to various Angolan 
localities, the 59R was the second more frequent dhfr 
mutation in Lubango, instead of the 51I [8–11]. In addi-
tion, it is worth to noting that the 164L pfdhfr SNP was 
also detected for the first time in Angola. This muta-
tion is rare in Africa [5] but its presence in association 
with 108N  +  51I and/or 59R [27] as well as with the 
dhfr + dhps quintuple mutant [5], confers high levels of 
in vivo and in vitro resistance that could render SP totally 
ineffective. The 164L mutation was also combined to 
cycloguanil resistance [28] and is commonly found in P. 
falciparum samples from Southwest Asia [29, 30] and 
South America [31]. The possible reason for the detec-
tion of mutant 164L in Lubango (north of Angola) and 
not in other correlate Angolan studies (North and Cen-
tral Angola) is, probably, due to the greater proximity of 
Lubango with Zambia, where the presence of quintuple 
mutants is greater than 50 % [3].
From previous reports, it was known that the triple 
African mutant (N51I + C59R + S108N) shares a com-
mon ancestry with resistant dhfr from Southeast Asia 
[32, 33]; this mutant emerged in Asia and was introduced 
later in Africa, including Angola [19, 20, 33–36]. With 
respect to dhfr mutation 50R, another non-frequent dhfr 
mutation in Africa, it  was also identified in this study. 
This low-grade pyrimethamine resistant mutant [27] was 
first described as specific of South American isolates [27] 
but, besides South America, it has already been described 
in Africa in isolates from Kenya [35], Central African 
Republic [37] and Angola [8].
In relation to dhps gene, the 437G mutation was the 
most common, reaching almost fixation, similarly to 
other Angolan localities [8, 10, 11] and other African 
countries [16, 20, 23, 26], especially in western and Cen-
tral Africa.
The dhps 540E mutation, less commonly observed in 
western Africa, was also identified in this study, confirm-
ing previous data from Luanda [7, 8], Cabinda, Huige, 
Kwanza Norte, Malange and Huambo [10]. However, the 
spatial distribution of this allele in Angolan provinces 
seems heterogeneous and even in the same province its 
frequency can vary overtime [9, 10]. Thus, screening for 
dhps 540E, a surrogate for the quintuple mutant, is a pri-
ority in West Africa where it is comparatively rare [3].
The combination of 437G with the triple mutant 
51I + 59R + 108N which is considered to be associated 
with SP treatment failure [38–40], was detected in 33 % of 
Lubango samples. However, in vitro studies showed that 
the single 437G mutant has a lesser degree of tolerance to 
sulfadoxine than the 437G + 540E double mutant. Thus, 
triple mutant 51I + 59R + 108N associated with single 
437G mutant could have a less detrimental effect on SP-
IPT than the associated 437G  +  540E mutations—the 
sustained protective efficacy of SP-IPTi in western and 
Central Africa reinforce these points [41].
Despite the presence of parasites with triple dhfr 
mutant at positions 51I, 59R and 108N (15 %) and double 
dhps mutant at positions 437G + 540E (7 %), the quin-
tuple mutant (51I + 59R + 108N + 437G + 540E), con-
sidered a significant predictor of SP treatment failure [42] 
was not detected in the studied isolates from Lubango. 
To date, this quintuple mutant was not observed in 
central and northern areas of Angola [7–11]. Besides 
Lubango, similar low frequencies of double 437G + 540E 
pfdhps mutant were described in Huambo (12.5 %) [10], 
Benguela (8 %) [10], Cabinda (5.3 %) [10], Malanje (3.1 %) 
[10], Luanda (3  %) [8], Kwanza Norte (2.1  %) [10] and 
Uige (1.9 %) [10], contrasting with the higher frequencies 
of this mutant detected in Eastern Africa: Kenya (86 %), 
Tanzania (90 %), Malawi (95 %) and Uganda (95 %). With 
the exception of Malanje (3.9  %), the frequencies of the 
triple 51I +59R +  108N dhfr mutant in Angolan prov-
inces, including Lubango, were higher than the double 
437G + 540E pfdhps mutant but, East African countries 
presented higher prevalence rates [43].
These findings are expected because East African coun-
tries presented a high rate of SP treatment failure of fal-
ciparum malaria together with the increased presence 
of the quintuple mutant considered the most specific 
molecular marker for SP [44, 45].
Table 4 Combined molecular dhfr and  dhps gene profiles 
in 25 samples of P. falciparum from Lubango, Angola
Genes Haplotypes Mutated
dhfr + dhps N/ % Type
51I/108 N + 437G ACICNVI + SGKAA 14/56 Double and single
59R/108 N + 437G ACNRNVI + SGKAA 5/20 Double and single
51I/59R/108 N + 437G ACIRNVI + SGKAA 6/24 Triple and single
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Besides quintuple mutants, the concept of “super resist-
ant genotypes” is emerging which further raise the thresh-
old of drug tolerance in parasites comprising additional 
mutations in combination with N51I  +  C59R  +  S108N 
and A437G  +  K540E [3]. The additional mutations are 
dhfr I164L (found in one sample; 2 %) and dhps A581G and 
A613T/S, which were not found in this study. Although, 
these mutations are rare, their impact on SP-IPTi or SP-
IPTp efficacy is considered highly detrimental [5]. When 
the quadruple mutant N51I + C59R + S108N + A437G 
occur in the absence of 540E, these parasite populations 
are classified as partially resistant genotypes, and its resist-
ance levels are not expected to be as high [3]. The efficacy 
of IPTp in western Africa, where N51I + C59R + S108N 
and A437G exist in combination with 581G but not with 
540E supports the view that these parasites should be 
regarded differently [3]. In this case, molecular markers of 
super resistance may be an important warning about fail-
ing efficacy of IPTp.
Many studies suggested that IPTp with SP remains 
effective, or at least it is not associated with harm, in 
areas with high prevalence of P. falciparum quintuple 
mutant parasites [46, 47]. There is not enough evidence 
yet to establish a threshold prevalence of the classical 
dhfr +  dfps quintuple mutant, or even of the dhps 581, 
dhps 540 or dhfr 164 point mutations above which there 
is a clear loss of IPTp-SP effectiveness. Therefore, the sig-
nificance of the additional mutation at codon 540 needs 
further investigation.
Conclusion
In view of the data reported here and elsewhere, it was 
conclude that, although the number of samples available 
for the present study was limited, pfdhfr and pfdhps gene 
mutations in isolates from Lubango are suggestive of a 
low-grade SP resistance and their presences highlight the 
importance of molecular markers screening to monitor 
the evolution of P. falciparum SP resistance in Angola.
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